Cargando…
Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
Tocilizumab is a fully humanized monoclonal antibody against interleukin-6 receptors that was approved for the treatment of patients with rheumatoid arthritis (RA). Several lines of evidence, obtained both from conventional disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor (T...
Autores principales: | Yilmaz, Sedat, Simsek, Ismail |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810895/ https://www.ncbi.nlm.nih.gov/pubmed/24179334 http://dx.doi.org/10.2147/TCRM.S35784 |
Ejemplares similares
-
Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008) -
Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014) -
Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2012) -
Management of rheumatoid arthritis in People’s Republic of China – focus on tocilizumab and patient considerations
por: Wang, Geng, et al.
Publicado: (2015) -
Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review
por: Al-Shakarchi, Israa, et al.
Publicado: (2013)